Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2017 | BSH 2017 lymphoma highlights: looking at synergies between immuno-oncology agents

Graham Collins • 27 Mar 2017
BSH 2017
Hodgkin Lymphoma Non-Hodgkin Lymphoma Antibodies

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil of Oxford University Hospitals NHS Foundation Trust, Oxford, UK discusses his highlights from the Free Lymphoma/CLL Communications session held at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Dr Collins highlights a presentation on preclinical research looking at potential synergies between immune-oncology agents; it showed the potential for a combination between anti-CD20 and anti-CD27 antibodies in lymphoma.

More from Graham Collins

2:02
Phase II ANIMATE trial investigating PET response-adapted treatment using nivolumab in R/R cHL
Graham Collins • 29 Apr 2024
1:19
Mechanism of action of BTK degraders and insights into NX-5948
Graham Collins • 16 Jun 2023
1:15
The benefits of glofitamab in R/R DLBCL post-CAR-T therapy
Graham Collins • 16 Jun 2023
1:30
The role of tafasitamab in the lymphoma treatment landscape & promising results from clinical trials
Graham Collins • 16 Jun 2023

Related Videos

2:04
Salvage treatment options following CAR-T failure in DLBCL
Jaromir Tomasik • 17 Apr 2024
1:55
Exploring first-line CAR-T therapy for the treatment of DLBCL
Wendy Osborne • 22 Apr 2024
3:29
CAR-T therapy as the SoC in 2L LBCL and barriers that remain
Wendy Osborne • 22 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals